Working… Menu
Trial record 84 of 174 for:    "Heart Disease" | "Heparin"

(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention) (REDUCED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01031095
Recruitment Status : Completed
First Posted : December 14, 2009
Results First Posted : October 10, 2013
Last Update Posted : January 30, 2014
Information provided by (Responsible Party):
Hasan ARI, Bursa Postgraduate Hospital

Brief Summary:

The hypothesis:

Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Other: coronary intervention Phase 3

Detailed Description:


Primary objective:To evaluate the efficiency and safety of low dose intracoronary unfractioned heparin (UFH) on elective percutaneous coronary intervention (PCI).

Secondary objective:

  • To evaluate the effect of low dose intracoronary UFH on myocardial ischemia after PCI.
  • To evaluate the effect of low dose intracoronary UFH on bleeding complications after PCI.
  • To evaluate the cost-effectivity of low dose intracoronary UFH on elective PCI

Study central:

  • Bursa Postgraduate Hospital, Cardiology Clinic

Study population:

  • we planned to enrol 200 patients.
  • Patients will randomise in two groups (control group:100 patients, study group:100 patients)

Study works:-Write case report form for all patients

  • Control for inclusion criteria
  • Demographic data (age, gender)
  • Height, weight, BMI and glomerular filtration rate (GFR)
  • Risk factors
  • laboratory data (biochemical and hematologic)
  • Medication history
  • Echocardiographic data
  • Angiographic data
  • Procedure time
  • PCI data(vessel diameter, stent diameter, lesion and stent length, performed percutaneous transluminal coronary angioplasty (PTCA) or not, etc)
  • Before and after procedure (activated clotting time) ACT value
  • Before and after procedure troponin I (TnI) and Creatine kinase MB (CKMB) levels
  • Note complication (MACE, bleeding, hematoma etc)
  • Note femoral compression time.

    4 weeks later note the first control data.

Six months later note the second control data.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention
Study Start Date : June 2009
Actual Primary Completion Date : December 2009
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
Drug Information available for: Heparin

Arm Intervention/treatment
Experimental: Low dose intracoronary heparin
Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
Other: coronary intervention
elective coronary intervention

Active Comparator: Standard treatment arm
Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
Other: coronary intervention
elective coronary intervention

Primary Outcome Measures :
  1. Major Adverse Cardiac Events [ Time Frame: 30 days ]
  2. Major Adverse Cardiac Event [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patients; who have planned elective PCI and have had written informed consent for participation to study.
  • The native coronary artery;

    • lesion with narrowing >=70%,
    • lesion without thrombus
    • no left main coronary artery (LMCA) lesion
    • no chronic total occlusion lesion

Exclusion Criteria:

  • Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin
  • Patients who performed primary PCI
  • Patients with acute coronary syndrome
  • Patients with have a history of myocardial infarction (MI) for two weeks
  • Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours
  • Patients on warfarin therapy
  • Patients who have bleeding diathesis, or have high risk for bleeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01031095

Layout table for location information
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Bursa, Turkey, 16320
Sponsors and Collaborators
Bursa Postgraduate Hospital
Layout table for investigator information
Study Director: Hasan Arı, MD Bursa Postgraduate Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hasan ARI, Bursa Postgraduate Hospital Identifier: NCT01031095     History of Changes
Other Study ID Numbers: BYİEAH1
First Posted: December 14, 2009    Key Record Dates
Results First Posted: October 10, 2013
Last Update Posted: January 30, 2014
Last Verified: December 2013
Keywords provided by Hasan ARI, Bursa Postgraduate Hospital:
percutaneous coronary intervention
low dose intracoronary heparin
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Calcium heparin
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action